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Abstract
Background: On Aug 9th 2004 Health Canada released an advisory, which followed a similar one
from the FDA regarding the use of SSRI's and other antidepressants during pregnancy and potential
adverse effects on newborns. In neither advisory was it stated that women should discontinue their
antidepressant. In the seven days following the release of this advisory, The Motherisk Program
received 49 calls from anxious women in response to the media reporting of this information.
Objective: To examine the impact of the advisory and subsequent reporting in the media, on the
decision-making of women, currently taking an antidepressant, who called The Motherisk Program
after becoming aware of this information.
Methods: We attempted to follow up all the women who had called us who were alarmed by this
advisory and asked them to complete a specially designed questionnaire.
Results: We were able to complete 43/49 (88%) follow-ups of the women who contacted us. All
of the callers reported that the messages in the media caused a great deal of anxiety. Seven
misunderstood the advisory, ie their children were more than 1 year old, five had discontinued
their antidepressant (3 abruptly (2 later restarted after speaking with Motherisk counsellors)and 2
with some form of tapering off) and(6) were considering discontinuation, but decided to continue
following reassurance from Motherisk
Conclusion: Medical information regarding fetal and infant safety, disseminated in the public
domain, should be transferred in a way that does not influence a pregnant woman to make
decisions that may not be in the best interest of hers or her child's health.
Background
The media plays a significant role in the dissemination of
medical information to the general public, through news-
papers, television, magazines and more recently through
the internet. While it is important to get these messages to
the public, at times it appears that the media may have a
different agenda, such as selling newspapers or widening
their TV audiences. They seem to prefer alarmist headlines
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and display a preference for stories that catch attention,
rather than to inform the public of new scientific data that
has both positive and negative results. For example, sto-
ries describing safe products are often unreported, or
reported in small print, whereas unsafe products usually
make headlines. [1] Since the thalidomide scare in the six-
ties, this has been especially true of stories concerning the
safety/risk of exposures during pregnancy.
A recent example in another field, can be found in the
study of the use of hormone replacement therapy (HRT)
following the release of The Women's Health Initiative
(WHI) which was widely publicized in the lay press. [2] A
recent survey, completed by more than 1000 women, that
examined their opinions and understanding from the lay
press of this study, found that women dramatically over-
estimated the risks of HRT.[3] Another study found that
information on the benefits of HRT was mainly provided
by health care professionals, whereas information on the
risks was provided mainly by the mass media. [4]
The Motherisk Program, at the Hospital for Sick Children
in Toronto, is a counseling service that provides pregnant,
breastfeeding women, and health care providers with evi-
dence-based information on the safety and risks of expo-
sures to prescription and over-the-counter (OTC)
medications, natural health products, chemicals, radia-
tion, and infectious agents. Women and their health care
professionals often call us when alarming stories regard-
ing pregnancy exposures are reported in the media. Con-
sequently, we receive a dramatic increase in the number of
calls to our service following a report in the media that
involves a study that has produced results that are distress-
ing to a pregnant woman.
On June 9th 2004 the FDA(Food and Drug Administra-
tion) instructed the manufacturers of antidepressants to
issue warnings about perinatal complications associated
with their products. FDA: Medwatch Drug Alert. June 03/
2004). On Aug 9th 2004, Health Canada, followed suit
and released on their website http://www.hc-sc.gc.ca/ an
advisory warning of the potential adverse effects of Selec-
tive Serotonin Reuptake Inhibitors (SSRI's) and other
antidepressants on newborns. It was stated that the advi-
sory was intended to increase awareness among mothers
and physicians of the possible symptoms that may occur
in the newborn, so that they can be recognized and
addressed quickly. Some of the symptoms listed were
from reports describing feeding and/or breathing difficul-
ties, seizures, muscle rigidity, jitteriness and constant cry-
ing. The advisory also stated that if a woman is pregnant
and taking an antidepressant she should discuss with her
health care professional the potential benefits and risks of
treatment options. It was also stated that it is very impor-
tant that women do NOT stop these medications without
consulting their doctor, however, physicians may con-
sider slowly decreasing the dose in the third trimester of
pregnancy. It must be noted, that nowhere in this advisory
was it stated that women should avoid taking antidepres-
sants during pregnancy. [5]
This advisory was reported in all forms of the media. Table
1 shows some examples, which were selected both ran-
domly and from the women's reports.
In the seven days following the media reports, we received
49 calls to the Motherisk line from anxious women. This
number was in addition to the already substantial number
of calls regarding the use of antidepressants we receive
each day. We were not surprised that there was this sud-
den influx of calls, as we felt that this advisory was clearly
ambiguous and it was understandable that the media may
have misinterpreted some of the intended message.
The objective of this study was to examine the impact of
the media translation of this advisory, on the decision-
making of women who were currently taking an antide-
pressant and called Motherisk for information.
Methods
Researchers at the Motherisk Program developed a ques-
tionnaire that consisted of 4 questions, (Appendix).
Potential participants were women currently treated with
an antidepressant who had contacted the Motherisk Pro-
gram after hearing about the Health Canada advisory in
the media and becoming alarmed.
After receiving evidence based information provided by a
Motherisk counselor, (table 2) each woman was followed
up by phone within one week of their initial call. Upon
contact, she was asked if she would be willing to partici-
pate in a telephone survey to be conducted by a student.
Oral consent was obtained from each participant after the
survey was fully explained over the telephone. If the inter-
viewer was unable to reach the women on the first con-
tact, two more attempts were made before giving up.
The data were analyzed by descriptive statistics.
Table 1: Samples of media reporting of advisory (headlines)
Radio: (Ottawa) "Antidepressants pose risk to unborn babies"
Internet: (Canada.com News) "Depression drugs can hurt babies"
Newspaper: (The Toronto Star)"Avoid antidepressants in pregnancy"
Television: (CTV) Antidepressants may put unborn babies at risk
Magazine: (Health and Wellness) "Pregnant women warned about 
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Results
A total of 49 women agreed to participate and 43 com-
pleted the survey, a response rate of 88%. Of the women
who agreed to participate but were lost to follow-up; 2
had incorrect telephone numbers (either because they had
given the wrong number or it had been noted incorrectly)
and 4 of the women were unavailable to complete the
questionnaire. All of the callers reported that the informa-
tion they received from the media caused a great deal of
anxiety. They all felt that this was important information
to know, however would not have been so alarmed if it
had been translated by the media in a less "scary" fashion.
The following results underscore how the information
was translated in such a misleading fashion. This informa-
tion was specifically aimed at women taking an antide-
pressant in late pregnancy. Thirty-two of the women were
not in the third trimester at the time they called the Moth-
erisk Program and eleven were not even pregnant. Four of
them were planning a pregnancy and seven had taken an
antidepressant when they were pregnant and their chil-
dren were now more than one year old. Three of the
women who stopped taking their antidepressant, discon-
tinued it abruptly, although two restarted following reas-
surance from Motherisk. Six women were considering
discontinuing their medication, but were reassured by
Motherisk and decided to continue. Table 2
Discussion
To our knowledge, this is the first survey of it's kind that
has been conducted to examine the impact of public
health advisories and the subsequent reports in the media
on the decision-making of pregnant women regarding
taking antidepressants during pregnancy. We were able to
interview a convenience sample of 43 women who had
called our line following the dissemination of this infor-
mation in the media. We did not set out to conduct a ran-
domized controlled study, we simply wanted to
document in an observational fashion, how the women
who called our program felt about the information they
had received. As such, we were unable to ascertain how
many other women in the general population were also
possibly negatively affected by rash decision-making
prompted by these stories in the media. Conversely, we
were also unable to examine how many women were
unaffected by the media attention to this advisory, as they
did not call us.
To date, based on a fairly substantial body of epidemio-
logic data, there is no evidence that antidepressants are
not safe to take during pregnancy [6], in fact, emerging
data in the literature documents evidence that not taking
an antidepressant if it is warranted may be more harmful.
The decision to discontinue taking an antidepressant dur-
ing pregnancy can have deleterious effects on both the
health of the mother and her baby as untreated depres-
sion during pregnancy carries its own risks. These include
adverse maternal outcomes such as: poor compliance
with prenatal care, inadequate nutrition, poor pregnancy
outcomes including increased risk of preterm delivery and
importantly, an increase risk of post partum depres-
sion.[7] Additionally, abrupt discontinuation of antide-
pressant medication during pregnancy can result in
serious physical and psychological adverse effects, which
may include substitution of alcohol for medication, acute
onset of a major depressive episode and suicidal ideation.
[8] Furthermore, studies of infants born to depressed
mothers have reported that these infants exhibit "depres-
sion-like behavior, demonstrated by decreased facial
expressions, inferior orientation skills, excitability and
abnormal reflexes.[9] Conversely, the neonatal SSRI poor
adaptation syndrome occurs in a minority of cases, is usu-
ally self-limited and to date there is no evidence to suggest
that a woman should discontinue her antidepressant in
late pregnancy.[10] However, the research is ongoing, so
it is not possible to say definitively how often this occurs
or that there are no long term adverse effects on the child
whose mother was exposed to an antidepressant in late
pregnancy. A woman and her physician should always
discuss the evidence-based information on both the posi-
tive and negative effects of treatment with an antidepres-
sant in pregnancy before making a decision, which will
ensure the best possible outcome for the mother and
child.
It is important that scientific information is disseminated
to the public to empower them to take care of their health.
Paternalistic models of health care delivery have been
replaced by a more balanced approach, which includes
both patient and provider goals Today, patients are
encouraged to actively participate in the decision-making
regarding management and treatment of their health and
Table 2: Evidence-based information given by Motherisk 
counsellors
1. Antidepressants are an important pharmacological tool in the 
treatment of depression, including during pregnancy.
2. Based on epidemiologic studies they are considered an exposure 
that would not harm the fetus.
3. Untreated maternal depression is associated with adverse effects 
on both the mother and the fetus.
4. In a minority of infants there is a mostly self limited but if required, 
treatable discontinuation syndrome. Consequently, the baby should 
be observed carefully after birth for signs of withdrawal.
5. If a woman has discussed the benefits and risks of taking an 
antidepressant during pregnancy with her physician and if the decision 
is to be pharmacologic treatment, based on current epidemiologic 
data, there is no reason to discontinue or decrease the drug anytime 
during pregnancy.BMC Pregnancy and Childbirth 2005, 5:11 http://www.biomedcentral.com/1471-2393/5/11
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the various forms of the news media particularly the Inter-
net are powerful tools to facilitate this process. However,
the way in which this information is translated from sci-
entific data and disseminated to the public must be car-
ried out in a responsible and circumspect fashion.
Shuchman et al. documented the four problem areas in
the reporting of medical information to the public by
journalists: sensationalism, biases and conflicts of inter-
est, lack of follow-up and stories that are not covered. [11]
Motherisk has previously shown that studies reporting
results that showed no harmful effects, were underre-
ported as compared to studies that reported results that
showed harmful effects, for example, the use of cocaine in
pregnancy.[12]
The major limitation of this study, is that we do not know
how this media translation of scientific information
affected the general population of pregnant women who
are taking antidepressants during pregnancy for example,
women who did not call Motherisk. It remains unclear
how many women may have suffered from preventable
adverse events secondary to abrupt discontinuation of
their antidepressant as a result of these news stories, as we
only have information regarding the women who did call
The Motherisk Program. On the other hand some women
may have been unaffected by these stories and continued
to take their medication without any concerns.
In summary, this is an example of how the news media in
their misguided reporting of information from a Health
Canada Advisory, which in itself was rather ambiguous,
influenced a number of pregnant women to make deci-
sions that may not have been in the best interests of their
health or the health of their unborn child.
Appendix
Questionnaire
1. Were you taking an antidepressant when you called
Motherisk for information?
YES NO
2. If no:
1) Did you stop taking the medicine:
Abruptly Gradually (i.e. taper off)
2) After speaking with Motherisk, did you restart the
antidepressant?
YES NO
3. After speaking with Motherisk, did you speak with your
MD?
1) YES NO
2) If Yes:
Did your MD recommend you continue to take the
antidepressant?
YES NO
3) If No,
why?__________________________________________
4) If Yes:
Did you continue to take the antidepressant?
YES No
4. In your own words, "what impact do you feel that the
media stories had on your decision making regarding
whether you took the antidepressant or not"?
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